News
HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $54 Price Target
18 Apr 24
News, Price Target, Reiteration, Analyst Ratings
UroGen Announces FDA Acceptance Of IND Application For UGN-103, A Next Generation Mitomycin-Based Formulation For Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
15 Apr 24
Biotech, News, FDA, General
HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $54 Price Target
4 Apr 24
News, Price Target, Reiteration, Analyst Ratings
UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals Alleging Infringement Of US Patent Numbers 9,040,074 And 9,950,069
3 Apr 24
News, Legal
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
25 Mar 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Oppenheimer Maintains Outperform on UroGen Pharma, Lowers Price Target to $34
15 Mar 24
News, Price Target, Analyst Ratings
UroGen Pharma Q4 EPS $(0.72) Misses $(0.68) Estimate, Sales $23.53M Beat $22.57M Estimate
14 Mar 24
Earnings, News
Earnings Scheduled For March 14, 2024
14 Mar 24
Earnings
Earnings Outlook For UroGen Pharma
13 Mar 24
Earnings
Press releases
UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024
3 May 24
Press Releases
UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
17 Apr 24
Press Releases
NorthStar Appoints Peter Pfreundschuh to Board of Managers
15 Apr 24
Press Releases
UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
15 Apr 24
Press Releases
UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
14 Mar 24
Press Releases
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
8 Mar 24
Press Releases
UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024
4 Mar 24
Press Releases